SLRX has 36-month beta value of 0.40. Analysts have mixed views on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for SLRX is 2.11M, and currently, short sellers hold a 2.27% ratio of that float. The average trading volume of SLRX on June 25, 2025 was 1.31M shares.
SLRX) stock’s latest price update
Salarius Pharmaceuticals Inc (NASDAQ: SLRX)’s stock price has gone rise by 506187 in comparison to its previous close of 1.05, however, the company has experienced a 91.97% increase in its stock price over the last five trading days. globenewswire.com reported 2025-04-16 that Decoy’s development of novel peptide-conjugate therapeutics arising from its proprietary IMP3ACT™ platform to benefit from Dr. Langer’s extensive scientific knowledge and experience Decoy’s development of novel peptide-conjugate therapeutics arising from its proprietary IMP3ACT™ platform to benefit from Dr. Langer’s extensive scientific knowledge and experience
SLRX’s Market Performance
Salarius Pharmaceuticals Inc (SLRX) has seen a 91.97% rise in stock performance for the week, with a 54.32% gain in the past month and a 24.88% surge in the past quarter. The volatility ratio for the week is 9.38%, and the volatility levels for the past 30 days are at 12.87% for SLRX. The simple moving average for the past 20 days is 43.33% for SLRX’s stock, with a -10.21% simple moving average for the past 200 days.
Analysts’ Opinion of SLRX
Many brokerage firms have already submitted their reports for SLRX stocks, with Ladenburg Thalmann repeating the rating for SLRX by listing it as a “Buy.” The predicted price for SLRX in the upcoming period, according to Ladenburg Thalmann is $3.80 based on the research report published on April 27, 2020 of the previous year 2020.
SLRX Trading at 54.28% from the 50-Day Moving Average
After a stumble in the market that brought SLRX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -83.33% of loss for the given period.
Stock Fundamentals for SLRX
The total capital return value is set at -7.5. Equity return is now at value -300.16, with -154.23 for asset returns.
Based on Salarius Pharmaceuticals Inc (SLRX), the company’s capital structure generated 0.64 points at debt to capital in total, while cash flow to debt ratio is standing at -38.79.
Currently, EBITDA for the company is -5.57 million with net debt to EBITDA at 0.3. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.89.
Conclusion
To put it simply, Salarius Pharmaceuticals Inc (SLRX) has had a mixed performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
